Pharmaceutical & Biotech News and Insights

Good news for GW Pharmaceutical’s epilepsy drug
New data from a Phase III study of GW Pharmaceuticals' in-development epilepsy drug shows a reduction the rates of seizures by more than 50%. The ... 
Read More


Teva to buy Auspex
Teva announced that they have entered into a definitive merger agreement with Auspex Pharmaceuticals. Teva will pay $101 per share, or about $3.2 billion for ... 
Read More


New Alzheimer's R&D project
With the number of people with dementia expected to triple by 2050, several industry giants are investing in a $100 million effort to find effective ... 
Read More


Astellas awarded FDA approval
Astellas was awarded FDA approval for Cresemba, an antifungal treatment for two rare but dangerous infections that commonly affect patients undergoing chemotherapy or who have ... 
Read More


Supply switch causing delays and cost changes for Genentech’ cancer drugs
A recent survey conducted by a hospital services company, Novation, has shown that since Genentech moved its best-selling cancer drugs to specialty distributors there have ... 
Read More


Baxter Picks HQ Location for its Biopharma Spinoff
Baxalta Incorporated, will set up shop in a 260,000 square foot building located in Bannockburn, IL, a short 6 mile trip up the road from ... 
Read More


Eisai gets an early FDA Approval
The FDA as awarded an early approval to Eisai for its new thyroid cancer drug. Lenvatinib, which will sell as Lenvima blocks the growth agent ... 
Read More


Millennium to become Takeda Oncology
Millennium, a Massachusetts based company that was purchased by Takeda in 2008, will soon become Takeda Oncology. The rebranding of the iconic biotech and an ... 
Read More


Merck to buy Cubist
As part of a plan to focus on its most promising businesses, Merck & Co. has entered an agreement to buy Cubist Pharmaceuticals. The cost ... 
Read More


Dendreon Files for Bankruptcy
Despite numerous cost cutting measures, Dendreon has filed for Chapter 11 bankruptcy protection. It wasn't too long ago that things looked promising for the company ... 
Read More


« prev - page 1 of 3 - next »